ArticleFrontiers in bioengineering and biotechnology2020
3D Bioprinting Pluripotent Stem Cell Derived Neural Tissues Using a Novel Fibrin Bioink Containing Drug Releasing Microspheres.
Article in Frontiers in bioengineering and biotechnology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
59 citing papers in PubMed, 3 syntheses or guidelines pooled it, 139 citations in OpenAlex.
- Building on a Solid Foundation: Adding Relevance and Reproducibility to Neurological Modeling Using Human Pluripotent Stem Cells.Frontiers in cellular neuroscience · 2021Pooled it
- Candidate Bioinks for Extrusion 3D Bioprinting-A Systematic Review of the Literature.Frontiers in bioengineering and biotechnology · 2021Pooled it
- Current strategies and opportunities to manufacture cells for modeling human lungs.Advanced drug delivery reviews · 2020Pooled it
- Emerging Nano Bioinks in Bioprinting: Functional Materials, Engineering Strategies, and Biomedical Applications.Materials (Basel, Switzerland) · 2026Review
- Advancing Stem Cell Bioprinting to Bridge Engineered and Natural Tissue Constructs.Advanced materials (Deerfield Beach, Fla.) · 2026Review
- Innovations in skin microphysiological systems for nonclinical testing and FDA modernization.Microsystems & nanoengineering · 2026Review
- Task-specific computational fluid dynamics evaluation of multi-outlet extrusion nozzles for bioprinting.Frontiers in bioengineering and biotechnology · 2026Article
- Regenerative medicine approaches for the treatment of peripheral nerve injuries: progress and challenges.Regenerative biomaterials · 2026Review
- Using silica nanoparticles to deliver antibiotics for treating Gram-positive bacterial infections in a 3D-bioprinted dermal model.Frontiers in bioengineering and biotechnology · 2026Article
- Next-Generation Biomaterials: Design Strategies, Clinical Translation, and the Rise of Intelligent Therapeutic Platforms.ACS omega · 2025Review
- 3D bioprinted human iPSC-derived neural progenitor cells as a novel platform for studying neurogenic niche.APL bioengineering · 2025Article
- Geometrical constraints dictate assembly and phenotype of human iPSC-derived motoneuronal spheroids.Stem cell research & therapy · 2025Article
- Brain organoids: building higher-order complexity and neural circuitry models.Trends in biotechnology · 2025Review
- Bioprinting of Alginate-Norbornene bioinks to create a versatile platform for kidneyBioactive materials · 2025Article
- Review
- Microspheres for 3D bioprinting: a review of fabrication methods and applications.Frontiers in bioengineering and biotechnology · 2025Review
- A 3D Bioprinted Human Neurovascular Unit Model of Glioblastoma Tumor Growth.Advanced healthcare materials · 2024Article
- Plant-Based Decellularization: A Novel Approach for Perfusion-Compatible Tissue Engineering Structures.Journal of microbiology and biotechnology · 2024Review
- Advancements of 3D bioprinting in regenerative medicine: Exploring cell sources for organ fabrication.Heliyon · 2024Review
- Biopolymers for Tissue Engineering: Crosslinking, Printing Techniques, and Applications.Gels (Basel, Switzerland) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
3D bioprinting combines cells with a supportive bioink to fabricate multiscale, multi-cellular structures that imitate native tissues. Here, we demonstrate how our novel fibrin-based bioink formulation combined with drug releasing microspheres can serve as a tool for bioprinting tissues using human induced pluripotent stem cell (hiPSC)-derived neural progenitor cells (NPCs). Microspheres, small spherical particles that generate controlled drug release, promote hiPSC differentiation into dopaminergic neurons when used to deliver small molecules like guggulsterone. We used the microfluidics based RX1 bioprinter to generate domes with a 1 cm diameter consisting of our novel fibrin-based bioink containing guggulsterone microspheres and hiPSC-derived NPCs. The resulting tissues exhibited over 90% cellular viability 1 day post printing that then increased to 95% 7 days post printing. The bioprinted tissues expressed the early neuronal marker, TUJ1 and the early midbrain marker, Forkhead Box A2 (FOXA2) after 15 days of culture. These bioprinted neural tissues expressed TUJ1 (15 ± 1.3%), the dopamine marker, tyrosine hydroxylase (TH) (8 ± 1%) and other glial markers such as glial fibrillary acidic protein (GFAP) (15 ± 4%) and oligodendrocyte progenitor marker (O4) (4 ± 1%) after 30 days. Also, quantitative polymerase chain reaction (qPCR) analysis showed these bioprinted tissues expressed
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.